$PLX
Protalix BioTherapeutics, Inc.

2024 Q3 Form 10-Q Financial Statement

#000155837024012134 Filed on August 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $17.96M $13.47M
YoY Change 73.6% -61.59%
Cost Of Revenue $8.375M $9.456M
YoY Change 71.16% 53.81%
Gross Profit $9.584M $4.018M
YoY Change 75.79% -86.11%
Gross Profit Margin 53.37% 29.82%
Selling, General & Admin $2.595M $3.484M
YoY Change -29.29% -13.57%
% of Gross Profit 27.08% 86.71%
Research & Development $2.998M $2.961M
YoY Change -18.29% -33.83%
% of Gross Profit 31.28% 73.69%
Depreciation & Amortization $319.0K
YoY Change 10.0%
% of Gross Profit 7.94%
Operating Expenses $5.593M $6.445M
YoY Change -23.79% -24.23%
Operating Profit $3.991M -$2.427M
YoY Change -311.5% -111.88%
Interest Expense $155.0K
YoY Change -120.13%
% of Operating Profit
Other Income/Expense, Net -$148.0K $155.0K
YoY Change -188.1% -120.03%
Pretax Income $3.843M -$2.272M
YoY Change -323.56% -111.56%
Income Tax $607.0K -$69.00K
% Of Pretax Income 15.79%
Net Earnings $3.236M -$2.203M
YoY Change -274.73% -111.39%
Net Earnings / Revenue 18.02% -16.35%
Basic Earnings Per Share $0.04 -$0.03
Diluted Earnings Per Share $0.03 -$0.03
COMMON SHARES
Basic Shares Outstanding 73.54M 73.32M
Diluted Shares Outstanding 81.22M 73.31M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $23.40M
YoY Change -51.45%
Cash & Equivalents $27.41M $23.40M
Short-Term Investments
Other Short-Term Assets $1.050M $1.493M
YoY Change -6.67% -12.59%
Inventory $17.20M $20.72M
Prepaid Expenses
Receivables $2.195M $10.13M
Other Receivables $0.00
Total Short-Term Assets $47.85M $77.37M
YoY Change -34.1% 5.15%
LONG-TERM ASSETS
Property, Plant & Equipment $4.648M $4.609M
YoY Change -0.77% -0.6%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.834M
YoY Change -12.86%
Total Long-Term Assets $13.71M $14.17M
YoY Change -8.3% -4.5%
TOTAL ASSETS
Total Short-Term Assets $47.85M $77.37M
Total Long-Term Assets $13.71M $14.17M
Total Assets $61.56M $91.54M
YoY Change -29.7% 3.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $19.58M $19.34M
YoY Change 4.47% 4.3%
Accrued Expenses $8.342M $9.387M
YoY Change -9.81% 9.05%
Deferred Revenue $12.70M
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $20.42M
YoY Change
Total Short-Term Liabilities $24.22M $57.97M
YoY Change -44.14% 150.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change -100.0%
Other Long-Term Liabilities $4.987M
YoY Change -19.56%
Total Long-Term Liabilities $4.906M $4.987M
YoY Change -17.73% -81.04%
TOTAL LIABILITIES
Total Short-Term Liabilities $24.22M $57.97M
Total Long-Term Liabilities $4.906M $4.987M
Total Liabilities $29.13M $62.96M
YoY Change -40.95% 27.41%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $32.44M $28.58M
YoY Change
Total Liabilities & Shareholders Equity $61.56M $91.54M
YoY Change -29.7% 3.53%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income $3.236M -$2.203M
YoY Change -274.73% -111.39%
Depreciation, Depletion And Amortization $319.0K
YoY Change 10.0%
Cash From Operating Activities -$3.610M
YoY Change -172.49%
INVESTING ACTIVITIES
Capital Expenditures $172.0K
YoY Change -14.0%
Acquisitions
YoY Change
Other Investing Activities -$8.000K
YoY Change -60.0%
Cash From Investing Activities -$180.0K
YoY Change -18.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -3.610M
Cash From Investing Activities -180.0K
Cash From Financing Activities
Net Change In Cash -3.790M
YoY Change -124.93%
FREE CASH FLOW
Cash From Operating Activities -$3.610M
Capital Expenditures $172.0K
Free Cash Flow -$3.782M
YoY Change -179.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001006281
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q4 us-gaap Assets
Assets
84434000
CY2024Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
4064000
CY2023Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
4320000
CY2024Q2 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
19343000
CY2023Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
19550000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1450000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1409000
CY2024Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
12695000
CY2024Q2 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
20420000
CY2023Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
20251000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
57972000
CY2024Q2 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
705000
CY2023Q4 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
714000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4282000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4621000
CY2024Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4987000
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
5335000
CY2024Q2 us-gaap Liabilities
Liabilities
62959000
CY2023Q4 us-gaap Liabilities
Liabilities
50865000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
28581000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
33569000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
91540000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
84434000
us-gaap Revenues
Revenues
17222000
us-gaap Revenues
Revenues
44663000
CY2024Q2 us-gaap Revenues
Revenues
13474000
CY2023Q2 us-gaap Revenues
Revenues
35075000
us-gaap Cost Of Revenue
CostOfRevenue
12058000
us-gaap Cost Of Revenue
CostOfRevenue
9233000
CY2024Q2 us-gaap Cost Of Revenue
CostOfRevenue
9456000
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
6148000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5848000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10322000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2961000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4475000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6599000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7146000
CY2024Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3484000
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4031000
us-gaap Operating Income Loss
OperatingIncomeLoss
-7283000
us-gaap Operating Income Loss
OperatingIncomeLoss
17962000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2427000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
20421000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
757000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
2169000
CY2024Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
367000
CY2023Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
1305000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-33357
dei Entity Registrant Name
EntityRegistrantName
PROTALIX BIOTHERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
65-0643773
dei Entity Address Address Line1
EntityAddressAddressLine1
2 University Plaza
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Hackensack
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07601
dei City Area Code
CityAreaCode
201
dei Local Phone Number
LocalPhoneNumber
696-9345
dei Security12b Title
Security12bTitle
Common stock, $0.001 par value
dei Trading Symbol
TradingSymbol
PLX
dei Security Exchange Name
SecurityExchangeName
NYSEAMER
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
73542674
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23399000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23634000
CY2024Q2 plx Short Term Bank Deposits
ShortTermBankDeposits
21630000
CY2023Q4 plx Short Term Bank Deposits
ShortTermBankDeposits
20926000
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10126000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5272000
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
1493000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1055000
CY2024Q2 us-gaap Inventory Net
InventoryNet
20719000
CY2023Q4 us-gaap Inventory Net
InventoryNet
19045000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
77367000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
69932000
CY2024Q2 us-gaap Defined Benefit Plan Assets For Plan Benefits Noncurrent
DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
535000
CY2023Q4 us-gaap Defined Benefit Plan Assets For Plan Benefits Noncurrent
DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
528000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4609000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4973000
CY2024Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
3299000
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
3092000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5730000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5909000
CY2024Q2 us-gaap Assets
Assets
91540000
CY2023Q4 us-gaap Assets
Assets
84434000
CY2024Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
4064000
CY2023Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
4320000
CY2024Q2 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
19343000
CY2023Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
19550000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1450000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1409000
CY2024Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
12695000
CY2024Q2 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
20420000
CY2023Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
20251000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
57972000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
45530000
CY2024Q2 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
705000
CY2023Q4 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
714000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4282000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4621000
CY2024Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4987000
CY2024Q2 us-gaap Liabilities
Liabilities
62959000
CY2023Q4 us-gaap Liabilities
Liabilities
50865000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
28581000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
33569000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
91540000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
84434000
us-gaap Revenues
Revenues
17222000
us-gaap Revenues
Revenues
44663000
CY2024Q2 us-gaap Revenues
Revenues
13474000
CY2023Q2 us-gaap Revenues
Revenues
35075000
us-gaap Cost Of Revenue
CostOfRevenue
12058000
us-gaap Cost Of Revenue
CostOfRevenue
9233000
CY2024Q2 us-gaap Cost Of Revenue
CostOfRevenue
9456000
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
6148000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5848000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10322000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2961000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4475000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6599000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7146000
CY2024Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3484000
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4031000
us-gaap Operating Income Loss
OperatingIncomeLoss
-7283000
us-gaap Operating Income Loss
OperatingIncomeLoss
17962000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
20421000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
757000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
2169000
CY2024Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
367000
CY2023Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
1305000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1035000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
918000
CY2024Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
522000
CY2023Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
531000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1035000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
918000
CY2024Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
522000
CY2023Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
531000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
278000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1251000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
155000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-774000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7005000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
16711000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2272000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
19647000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-207000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
503000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-69000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
308000
us-gaap Net Income Loss
NetIncomeLoss
-6798000
us-gaap Net Income Loss
NetIncomeLoss
16208000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2203000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
19339000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.26
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.29
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.18
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73172980
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62378745
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73308281
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67158628
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73172980
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78896220
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73308281
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83200641
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-10640000
plx Stock Issued During Period Value Sales Agreement
StockIssuedDuringPeriodValueSalesAgreement
23954000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
7783000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
812000
plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures
ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
172000
plx Stock Issued During Period Value Warrants Exercises
StockIssuedDuringPeriodValueWarrantsExercises
712000
us-gaap Net Income Loss
NetIncomeLoss
16208000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
39001000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
33569000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
833000
plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures
ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
1146000
us-gaap Net Income Loss
NetIncomeLoss
-6798000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1008000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
278000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1251000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
155000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-774000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7005000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2272000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
19647000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-207000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
503000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-69000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
308000
us-gaap Net Income Loss
NetIncomeLoss
-6798000
us-gaap Net Income Loss
NetIncomeLoss
16208000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2203000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
19339000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.26
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.29
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.18
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73172980
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62378745
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73308281
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67158628
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73172980
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78896220
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73308281
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83200641
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-10640000
plx Stock Issued During Period Value Sales Agreement
StockIssuedDuringPeriodValueSalesAgreement
23954000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
7783000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
812000
plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures
ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
172000
plx Stock Issued During Period Value Warrants Exercises
StockIssuedDuringPeriodValueWarrantsExercises
712000
us-gaap Net Income Loss
NetIncomeLoss
16208000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
39001000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
33569000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
833000
plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures
ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
1146000
us-gaap Net Income Loss
NetIncomeLoss
-6798000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
28581000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1008000
CY2023Q2 plx Stock Issued During Period Value Sales Agreement
StockIssuedDuringPeriodValueSalesAgreement
9721000
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
7783000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
359000
CY2023Q2 plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures
ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
79000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
359000
CY2023Q2 plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures
ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
79000
CY2023Q2 plx Stock Issued During Period Value Warrants Exercises
StockIssuedDuringPeriodValueWarrantsExercises
712000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
19339000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
39001000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
29786000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
333000
CY2024Q2 plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures
ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
665000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2203000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
28581000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
185000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
185000000
us-gaap Profit Loss
ProfitLoss
-6798000
us-gaap Profit Loss
ProfitLoss
16208000
us-gaap Share Based Compensation
ShareBasedCompensation
1979000
us-gaap Share Based Compensation
ShareBasedCompensation
984000
us-gaap Depreciation
Depreciation
641000
us-gaap Depreciation
Depreciation
573000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
975000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
152000
us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
16000
us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
36000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-207000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-3130000
plx Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement
GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
10000
plx Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement
GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
27000
plx Gain Loss On Debt Conversion
GainLossOnDebtConversion
421000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
148000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
12695000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5308000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-119000
plx Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
-20000
plx Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
-3000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1674000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2831000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
199000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3643000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
578000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1975000
plx Proceeds From Sale Of Short Term Deposits
ProceedsFromSaleOfShortTermDeposits
5000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
770000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
452000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
16000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
38000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-786000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4510000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
23954000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
712000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
19339000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
39001000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
29786000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
333000
CY2024Q2 plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures
ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
665000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2203000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
28581000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
185000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
185000000
us-gaap Profit Loss
ProfitLoss
-6798000
us-gaap Profit Loss
ProfitLoss
16208000
us-gaap Share Based Compensation
ShareBasedCompensation
1979000
us-gaap Share Based Compensation
ShareBasedCompensation
984000
us-gaap Depreciation
Depreciation
641000
us-gaap Depreciation
Depreciation
573000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
975000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
152000
us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
16000
us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
36000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-207000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-3130000
plx Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement
GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
10000
plx Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement
GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
27000
plx Gain Loss On Debt Conversion
GainLossOnDebtConversion
421000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
148000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-13178000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5308000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-119000
plx Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
-20000
plx Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
-3000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1674000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2831000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
199000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3643000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
578000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1975000
plx Proceeds From Sale Of Short Term Deposits
ProceedsFromSaleOfShortTermDeposits
5000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
770000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
452000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
16000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
38000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-786000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4510000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
23954000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
712000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
24666000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-27000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-78000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
24666000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-27000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-78000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-235000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
31073000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23634000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17111000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23399000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48184000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
121000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
258000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1079000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
7783000
us-gaap Interest Paid Net
InterestPaidNet
766000
plx Interest Received Net
InterestReceivedNet
78000
CY2024Q2 plx Number Of Global Licensing And Supply Agreements
NumberOfGlobalLicensingAndSupplyAgreements
2
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16158086
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1896733
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
31744960
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
31791645
CY2023Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
20251000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
415045000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
381549000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-235000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
31073000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23634000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17111000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23399000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48184000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
121000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
348000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
258000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1079000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
7783000
us-gaap Interest Paid Net
InterestPaidNet
766000
us-gaap Interest Paid Net
InterestPaidNet
1977000
plx Interest Received Net
InterestReceivedNet
56000
plx Interest Received Net
InterestReceivedNet
78000
CY2024Q2 plx Number Of Global Licensing And Supply Agreements
NumberOfGlobalLicensingAndSupplyAgreements
2
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16158086
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1896733
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
31744960
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
31791645
CY2023Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
20251000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
415045000
CY2024Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
4301000
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
4176000
CY2024Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
10874000
CY2023Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
9055000
CY2024Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
5544000
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
5814000
CY2024Q2 us-gaap Inventory Net
InventoryNet
20719000
CY2023Q4 us-gaap Inventory Net
InventoryNet
19045000
CY2024Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
4301000
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
4176000
CY2024Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
10874000
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
5814000
CY2024Q2 us-gaap Inventory Net
InventoryNet
20719000
CY2023Q4 us-gaap Inventory Net
InventoryNet
19045000
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
3633000
CY2023Q2 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
3438000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-207000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-3130000
CY2024Q2 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-69000
CY2023Q2 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-3130000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-207000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
503000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-69000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
308000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.03
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.07
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023Q2 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-3100000
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
3633000
CY2023Q2 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
3438000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-207000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-3130000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.03
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.07
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023Q2 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-3100000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1205000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1437000
CY2024Q2 us-gaap Interest Payable Current
InterestPayableCurrent
506000
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
511000
CY2024Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
1688000
CY2023Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
1605000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9387000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9009000
CY2024Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
509000
CY2023Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
637000
CY2024Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
2876000
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
2876000
CY2024Q2 plx Reserve For Deductions From Revenue Current
ReserveForDeductionsFromRevenueCurrent
3051000
CY2023Q4 plx Reserve For Deductions From Revenue Current
ReserveForDeductionsFromRevenueCurrent
2861000
CY2024Q2 plx Accounts Payable Property And Equipment Suppliers Current
AccountsPayablePropertyAndEquipmentSuppliersCurrent
121000
CY2023Q4 plx Accounts Payable Property And Equipment Suppliers Current
AccountsPayablePropertyAndEquipmentSuppliersCurrent
614000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
19343000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
19550000
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1205000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1437000
CY2024Q2 us-gaap Interest Payable Current
InterestPayableCurrent
506000
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
511000
CY2024Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
1688000
CY2023Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
1605000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9387000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9009000
CY2024Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
509000
CY2023Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
637000
CY2024Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
2876000
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
2876000
CY2024Q2 plx Reserve For Deductions From Revenue Current
ReserveForDeductionsFromRevenueCurrent
3051000
CY2023Q4 plx Reserve For Deductions From Revenue Current
ReserveForDeductionsFromRevenueCurrent
2861000
CY2024Q2 plx Accounts Payable Property And Equipment Suppliers Current
AccountsPayablePropertyAndEquipmentSuppliersCurrent
121000
CY2023Q4 plx Accounts Payable Property And Equipment Suppliers Current
AccountsPayablePropertyAndEquipmentSuppliersCurrent
614000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
19343000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
19550000
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-012134-index-headers.html Edgar Link pending
0001558370-24-012134-index.html Edgar Link pending
0001558370-24-012134.txt Edgar Link pending
0001558370-24-012134-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
plx-20240630.xsd Edgar Link pending
plx-20240630x10q.htm Edgar Link pending
plx-20240630x10q005.jpg Edgar Link pending
plx-20240630x10q007.jpg Edgar Link pending
plx-20240630x10q008.jpg Edgar Link pending
plx-20240630xex31d1.htm Edgar Link pending
plx-20240630xex31d2.htm Edgar Link pending
plx-20240630xex32d1.htm Edgar Link pending
plx-20240630xex32d2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
plx-20240630_def.xml Edgar Link unprocessable
plx-20240630_lab.xml Edgar Link unprocessable
plx-20240630_pre.xml Edgar Link unprocessable
plx-20240630_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
plx-20240630x10q_htm.xml Edgar Link completed